AdaptHealth Corp.

AdaptHealth Corp. is a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment (HME), medical supplies, and related services ¹. The company operates across four reportable segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home ². As of December 31, 2025, AdaptHealth serviced approximately 4.3 million patients annually in all 50 states through a network of approximately 640 locations in 48 states ³. The HME market is fragmented and highly competitive, with AdaptHealth competing against large national providers such as Accendra Health, Lincare Holdings Inc., Rotech Healthcare, Inc., Cardinal Health, Inc., and Quipt Home Medical Corp., as well as regional and product-specific providers, and non-HME providers like CVS and Amazon ⁴. AdaptHealth believes its competitive advantages include quality of patient care, efficient referral processes, a differentiated technology platform, a comprehensive product offering, a broad network of payor contracts, and overall ease of doing business ⁵.

AdaptHealth's core business model involves delivering HME products and services directly to patients' homes upon discharge from a hospital or receipt of a physician referral ⁶. Revenue is generated through three primary methods: resupply and one-time sales, fixed monthly equipment reimbursements, and at-risk capitation arrangements ⁷. Resupply and one-time sales, which include consumables like PAP masks, continuous glucose monitors (CGM), diabetes management supplies, and wound care supplies, accounted for approximately 63% of net revenue for the year ended December 31, 2025 ⁸. Fixed monthly equipment reimbursements for HME products such as oxygen and home mechanical ventilation equipment, PAP equipment, and hospital beds, accounted for approximately 33% of net revenue for the same period ⁹. At-risk capitation arrangements, where the company receives a per member per month (PMPM) fee to manage a range of healthcare services, accounted for approximately 4.0% of net revenue for the year ended December 31, 2025 ¹⁰.

The Sleep Health segment provides sleep therapy equipment, supplies, and related services for obstructive sleep apnea, including continuous positive airway pressure and BiLevel services ¹¹. This segment generated $1,378.147 million in net revenue for the year ended December 31, 2025, representing 42.5% of total net revenue ¹². Its Adjusted EBITDA was $310.559 million, with an Adjusted EBITDA Margin of 22.5% ¹³.

The Respiratory Health segment offers oxygen and home mechanical ventilation equipment and supplies, along with chronic therapy services for respiratory diseases ¹⁴. This segment contributed $691.160 million in net revenue for the year ended December 31, 2025, or 21.2% of total net revenue ¹⁵. Its Adjusted EBITDA was $209.749 million, achieving an Adjusted EBITDA Margin of 30.3% ¹⁶.

The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services for diabetes treatment ¹⁷. This segment reported $592.413 million in net revenue for the year ended December 31, 2025, accounting for 18.3% of total net revenue ¹⁸. Its Adjusted EBITDA was $26.073 million, with an Adjusted EBITDA Margin of 4.4% ¹⁹.

The Wellness at Home segment delivers home medical equipment and services to patients, including those discharged from acute care facilities, providing essential medical supplies and durable medical equipment ²⁰. This segment generated $583.137 million in net revenue for the year ended December 31, 2025, representing 18.0% of total net revenue ²¹. Its Adjusted EBITDA was $70.300 million, with an Adjusted EBITDA Margin of 12.1% ²².

For the fiscal year ended December 31, 2025, AdaptHealth reported total net revenue of $3,244.857 million ²³. The company incurred a net loss attributable to AdaptHealth Corp. of $(70.794) million ²⁴, resulting in a diluted EPS of $(0.52) ²⁵. Gross profit, calculated as net revenue less cost of net revenue, was $609.199 million ²⁶, yielding a gross margin of 18.8% ²⁷. Operating income was $90.873 million ²⁸, with an operating margin of 2.8% ²⁹. Free cash flow for the year was $219.383 million ³⁰. As of December 31, 2025, cash and equivalents stood at $106.136 million ³¹, total debt (excluding unamortized deferred financing fees) was $1,750.000 million ³², and net debt, calculated as total debt less cash, was $1,643.864 million ³³.

Comparing the year ended December 31, 2025, to the prior year, total net revenue decreased by $16.118 million, or 0.5% ³⁴. This was driven by a $92.427 million decrease from dispositions, partially offset by $56.857 million in organic revenue growth and $19.452 million from acquisitions ³⁵. Sleep Health net revenue increased by $28.9 million, or 2.1%, primarily due to higher patient census from PAP resupply products, though partially offset by lower sleep rental products ³⁶. Respiratory Health net revenue increased by $40.0 million, or 6.1%, driven by higher fixed monthly equipment reimbursements from increased patient census for oxygen equipment ³⁷. Diabetes Health net revenue decreased by $22.0 million, or 3.6%, mainly due to a shift in payor mix from commercial insurance to government payors, despite growth in patient census for insulin pumps and supplies ³⁸. Wellness at Home net revenue decreased by $63.1 million, or 9.8%, primarily due to the disposition of certain incontinence and infusion businesses in 2025 and custom rehab technology assets in 2024 ³⁹. The overall cost of net revenue increased by $55.8 million, or 2.2% ⁴⁰, leading to a decrease in gross margin from 20.9% in 2024 to 18.8% in 2025 ⁴¹. Operating income decreased by $172.859 million, or 65.5%, from $263.732 million in 2024 to $90.873 million in 2025 ⁴².

During the year ended December 31, 2025, AdaptHealth completed the disposition of certain incontinence and infusion businesses within its Wellness at Home segment, resulting in total pre-tax gains of $32.602 million ⁴³. The company also acquired certain assets of four home medical equipment providers and 100% of the equity interests in one provider, with total cash consideration of $42.8 million and a deferred payment of $0.3 million ⁴⁴. In the fourth quarter of 2025, AdaptHealth recognized a non-cash goodwill impairment charge of $128.0 million related to its Diabetes Health reporting unit ⁴⁵. The company also settled a class action complaint for $35.0 million, with $34.0 million funded by insurance carriers and $1.0 million by the company ⁴⁶.

The filing does not contain specific revenue, margin, or EPS guidance for the upcoming period.

AdaptHealth's strategic growth plan involves increasing its density in established markets and expanding its geographic footprint into new markets ⁴⁷. This growth strategy historically included acquisitions of home medical equipment providers, which remains an element of the company's strategy ⁴⁸. The company continuously reviews a pipeline of potential acquisition candidates and leverages the acquisition of equipment from previous providers to facilitate patient transitions related to newly awarded at-risk capitated contracts, with revenue from these new contracts considered organic ⁴⁹.

The company is deploying innovative programs, including artificial intelligence (AI) and generative AI, to improve or enhance patient and operational workflows ⁵⁰. This involves both internal resources and strategic partnerships focused on patient experience and operational efficiencies ⁵¹. AdaptHealth's primary mitigation efforts against inflationary pressures include utilizing its purchasing power in negotiations with vendors and increasing the use of technology, such as its digital platform for prescriptions, orders, and delivery, to drive operating efficiencies and control costs ⁵².

AdaptHealth's planned capital allocation includes continued investment in its affiliated facilities and equipment to meet regulatory standards, operate efficiently, and remain competitive ⁵³. The expansion of its business through acquisitions, facility expansion, and new facility construction may require additional capital ⁵⁴. As of December 31, 2025, the company had $106.136 million in cash ⁵⁵. The 2024 Credit Agreement, which matures in September 2029, includes a $650 million term loan and $300 million in revolving credit commitments ⁵⁶. As of December 31, 2025, $315.0 million was outstanding under the 2024 Term Loan, with quarterly principal repayments of $4.1 million through September 30, 2026, increasing to $8.1 million thereafter ⁵⁷. Subsequent to December 31, 2025, the company borrowed $100.0 million under the 2024 Revolver for working capital and general corporate purposes ⁵⁸. AdaptHealth also has $1,435.0 million aggregate principal amount of unsecured senior notes outstanding, including $600.0 million of 5.125% Senior Notes due March 1, 2030, $500.0 million of 4.625% Senior Notes due August 1, 2029, and $350.0 million of 6.125% Senior Notes due August 1, 2028 ⁵⁹. In November 2025 and January 2026, the company repurchased $15.0 million and $10.0 million aggregate principal amount of the 6.125% Senior Notes, respectively ⁶⁰. The company's matching contribution expense to its retirement plan was $8.5 million for the year ended December 31, 2025 ⁶¹.

Management explicitly flagged several structural headwinds and execution risks. The company's ability to obtain additional financing on acceptable terms, or at all, may be limited by economic conditions and restrictions in existing indebtedness, which could delay or abandon growth strategies ⁶². The competitive bidding process for Durable Medical Equipment, Prosthetics, Orthotics, & Supplies (DMEPOS) is expected to resume in 2026, with contracts awarded in late summer/early fall 2027 and effective no later than January 1, 2028 ⁶³. This resumption could further alter reimbursement rates and payment methodologies for certain DME items, potentially depressing reimbursement rates ⁶⁴. The One Big Beautiful Bill Act (OBBBA), enacted on July 4, 2025, introduces significant changes to U.S. healthcare policy, including new limitations and eligibility requirements for Medicaid, which are expected to reduce federal Medicaid expenditures and enrollment ⁶⁵. The OBBBA also contains policy changes expected to decrease the number of individuals obtaining health insurance from Affordable Care Act (ACA) marketplace platforms ⁶⁶. Any reduction in covered lives or changes to Medicaid eligibility and benefit structures could adversely affect utilization, reimbursement levels, and AdaptHealth's revenues ⁶⁷. Furthermore, the OBBBA authorizes states to impose Medicaid work requirements and related eligibility conditions, which may further reduce Medicaid enrollment or increase administrative disenrollment ⁶⁸.

AdaptHealth faces material risks from its reliance on a relatively small number of suppliers for patient service equipment and supplies, which could be disrupted by price increases, supply chain issues, or new tariffs, potentially causing delays and revenue losses ⁶⁹. The company is also exposed to economy-wide labor shortages and increased labor costs, which could materially adversely affect its business ⁷⁰. Inflation and rising interest rates have negatively impacted, and may continue to impact, AdaptHealth by increasing costs for labor, equipment, products, shipping, and warehousing, and by increasing interest expense on variable rate indebtedness ⁷¹. Cybersecurity attacks or security breaches on AdaptHealth's or its vendors' information systems could lead to data loss, operational disruptions, legal liability under HIPAA and other data protection laws, and reputational damage ⁷². The use of artificial intelligence (AI) technologies, including generative AI, by AdaptHealth or third parties, while offering benefits, also poses risks of misuse, flawed models, legal or regulatory exposure, and competitive harm ⁷³. AdaptHealth's financial performance is vulnerable to continuing efforts by private third-party payors to control costs, which may lead to lower reimbursement rates or contract renegotiations/terminations ⁷⁴. Changes in governmental or private payor supply replenishment schedules, particularly for sleep therapy supplies, could adversely affect revenue ⁷⁵. The company generates a significant portion of its revenue from sleep therapy equipment and supplies, making its success highly dependent on the continued adoption and market acceptance of these items ⁷⁶. Consolidation among health insurers and other industry participants could negatively affect AdaptHealth's negotiating leverage and competitive position ⁷⁷. Failure to manage the complex and lengthy reimbursement process, including collecting accounts receivable, could adversely affect revenue and financial results ⁷⁸. The company faces intense competition from numerous other sleep therapy, home respiratory, mobility equipment, and diabetes medical device providers, including large national players, regional providers, and new entrants like pharmacy benefit managers and technology companies, which could adversely affect revenues ⁷⁹. Changes in medical equipment technology and the development of new treatments, such as GLP-1 receptor agonist drugs for obesity and type 2 diabetes, could render current equipment or services obsolete and reduce demand ⁸⁰. AdaptHealth's operations involve the transport of compressed and liquid oxygen, carrying inherent risks of accidents and potential substantial losses, and its medical gas facilities are subject to extensive FDA and state regulations, requiring significant compliance oversight and expenses ⁸¹. Outsourcing portions of internal business functions to third-party providers carries risks of non-compliance, service disruptions, increased costs, and data protection failures ⁸². The company's ability to attract and retain key personnel, including senior management, is crucial, and the loss of such personnel could negatively impact operations and financial results ⁸³. AdaptHealth's strategic growth plan, which involves acquisitions, may not succeed due to increased competition for acquisition candidates, difficulties in integration, or failure to realize anticipated benefits and synergies ⁸⁴. Political and economic conditions, including global developments, tariffs, government shutdowns, international conflicts, natural disasters, and public health crises, are beyond AdaptHealth's control and could adversely affect its revenue and financial condition ⁸⁵. The company's current insurance program is expensive and may not adequately cover all losses, particularly if claims exceed coverage limits or if insurance companies change coverage terms or increase premiums ⁸⁶. AdaptHealth is subject to federal and state healthcare fraud and abuse and false claims laws, with increased prosecutions, and non-compliance could lead to substantial penalties, fines, and exclusion from government programs ⁸⁷. Failure to successfully design, modify, and implement technology-based and other process changes to maximize productivity and ensure compliance could negatively impact financial condition and reputation ⁸⁸. If CMS requires prior authorization or implements changes in documentation for AdaptHealth's products, particularly for items on the Master List or Required Prior Authorization List, revenue could be negatively impacted ⁸⁹. Furthermore, if CMS pursues payment reductions for continuous glucose monitors (CGMs) and supplies, as recommended by the OIG-HHS report, AdaptHealth's revenue, financial condition, and results of operations could be negatively impacted ⁹⁰. Reimbursement claims are subject to audits by governmental and private payor entities, and negative findings could lead to overpayment liability, refunds, payment suspensions, or revocation of billing privileges ⁹¹. Significant reimbursement reductions and/or exclusion from markets or product lines, particularly from the resumption of the DMEPOS Competitive Bidding Program, could materially adversely affect financial condition and results of operations ⁹². Failure to maintain required state and federal licenses and accreditation could impact operations, leading to interruptions, refunds, sanctions, or inability to serve Medicare beneficiaries ⁹³. Actual or perceived failures to comply with applicable data protection, privacy, security, and consumer protection laws, including HIPAA, HITECH Act, and CCPA, could adversely affect AdaptHealth's business, reputation, and financial condition ⁹⁴. Global climate change and related legal, regulatory, or market responses could impair the availability and cost of products and energy, and lead to physical damage to facilities or business interruption ⁹⁵. If AdaptHealth were required to write down all or part of its goodwill, its net earnings and net worth could be materially adversely affected, as demonstrated by the $128.0 million goodwill impairment charge in 2025 ⁹⁶. The company may not be able to generate sufficient cash flow to cover required payments or comply with financial and operating covenants under its long-term debt and operating leases, which could result in defaults and acceleration of debt ⁹⁷. AdaptHealth may need additional capital to fund its operating subsidiaries and finance its growth, and if it cannot obtain it on acceptable terms, its ability to grow may be limited ⁹⁸.

Management's overall tone emphasizes AdaptHealth's position as a national leader in patient-centered, healthcare-at-home solutions, highlighting its four reportable segments and extensive patient network ⁹⁹. They acknowledge the impact of inflation and supply chain disruptions, stating that mitigation efforts include leveraging purchasing power with vendors and increasing the use of technology to drive operating efficiencies and control costs, such as their digital platform for prescriptions, orders, and delivery ¹⁰⁰. A key strategic priority is continuing to grow through accretive acquisitions, reviewing a pipeline of potential candidates, and leveraging acquisitions to facilitate patient transitions for new at-risk capitated contracts ¹⁰¹. Another strategic priority is the deployment of innovative programs, including artificial intelligence (AI) and generative AI, to improve and enhance patient and operational workflows, involving both internal resources and strategic partnerships ¹⁰². Management also highlights their commitment to human capital resources, focusing on attracting and retaining highly motivated, well-qualified employees and executives through competitive salaries and benefits, and fostering a culture of diversity, inclusion, respect, excellence, compassion, and teamwork ¹⁰³.